A $2.1 Billion Fund Just Bought These 3 Stocks

Michael Douglass • 6 minute read
Reviewed by: Michael Douglass
Last updated Nov 16, 2026

@mezuna from dzul kifli's Images via Canva, @Casper1774Studio from Getty Images via Canva

Key Takeaways

  • Mizuho Markets Cayman LP’s latest 13F shows new stakes in Target and AbbVie and an 85% bigger stake in Synopsys by Sept. 30.
  • Target is the fund’s real bet, at nearly 10% of its 13F stocks, while AbbVie and Synopsys are under 2% each.
  • Target and AbbVie now trade close to Wall Street’s average price targets after strong runs.
  • Synopsys has the most upside per analysts’ estimates, with the average target 30% above the stock.

A fund most investors have never heard of just disclosed three moves worth a look. Mizuho Markets Cayman LP’s 13F for the quarter ended Sept. 30, filed Nov. 9, shows new stakes in Target (TGT) and AbbVie (ABBV), and a much bigger one in Synopsys (SNPS).

The filing lists $2.12 billion of US stocks across 79 positions. (A 13F shows only what a fund held on the last day of the quarter, so it can’t tell us what it paid or why.)

Target is the real bet

Target was new in the quarter, and it went straight in as the fund’s No. 5 position: 1.29 million shares worth $202 million at Sept. 30, or 9.6% of its 13F stocks. That’s far bigger than the AbbVie and Synopsys stakes combined.

The turnaround under CEO Michael Fiddelke, who took over on Feb. 1, is showing up in the numbers. Comparable sales rose 5.6% in the quarter ended May 2, Target’s biggest gain since early 2022, then 3.8% in the second quarter, when it raised its full-year outlook with help from tariff refunds. Fiddelke isn’t celebrating yet: “Two strong quarters is not the goal,” he told reporters in August.

Wall Street has followed the stock up, lifting its average target from $101 a year ago to $166:

Line chart from TIKR of Target's analysts' consensus (mean) price target, $ per share, last year.
Target (TGT): analysts’ consensus (mean) price target, $ per share, last year (TIKR)

The stock went from $90.62 to $161.45 over the same year, so it now sits just 3% below that average, at about 17x forward earnings. The stock is up 3% since Sept. 30, and Target’s third-quarter report this week has to keep comparable sales growing to push those targets higher.

TIKR tracks 38 analysts on Target. How many say “Buy”?

See the full breakdown of Buy, Hold, and Sell ratings on Target, along with Wall Street’s revenue and earnings estimates, all in one place. More than 500,000 investors use TIKR to research stocks like this one. See Target’s Analyst Ratings

AbbVie has already run

AbbVie was new too, though at a much smaller size: 133,558 shares worth $35 million at Sept. 30, 1.7% of the fund and its No. 9 position. The stock is up 13% since then, and the business gave it good reason.

On Oct. 30, AbbVie beat its own third-quarter guidance, with revenue up 10.3% to $17.4 billion and adjusted EPS of $3.82. Skyrizi sold $5.78 billion, up 22.7%, and Rinvoq rose 23.9%. Management raised its 2026 adjusted EPS guidance to $13.95-$13.99 and raised the quarterly dividend 5.2% to $1.82 a share.

Analysts have raised their sights all year, with the average target up from $242 to $312:

Line chart from TIKR of AbbVie's analysts' consensus (mean) price target, $ per share, last year.
AbbVie (ABBV): analysts’ consensus (mean) price target, $ per share, last year (TIKR)

That average now sits just 6% above the stock. And at about 19x forward earnings, AbbVie trades well above its five-year average of 14x and its previous quarter-end high of 18x, from September 2025. Investors are already paying for Skyrizi and Rinvoq to keep growing this fast, though management says Skyrizi’s data protection runs only to 2031. AbbVie’s 2027 guidance, due with its fourth-quarter results in early February, will show whether that price holds up.

Synopsys has the most room

Synopsys is the smallest of the three, at 61,730 shares worth $27 million, or 1.3% of the fund. But it’s the one the fund added to, raising its share count 85% on the quarter before.

The stock is up 5% since Sept. 30, yet still 16% below its 52-week high, even as the business keeps beating estimates. In early September, Synopsys reported fiscal third-quarter adjusted EPS of $3.91, against the $3.67 analysts expected, and revenue up 42.4% to $2.48 billion with Ansys, the simulation software maker it bought last year, in the numbers. It raised its full-year outlook, and the stock fell anyway.

Analysts haven’t backed off. Their average target has edged up from $556 a year ago to $590:

Line chart from TIKR of Synopsys' analysts' consensus (mean) price target, $ per share, last year.
Synopsys (SNPS): analysts’ consensus (mean) price target, $ per share, last year (TIKR)

That’s 30% above the stock, which closed at $455.20, and even the lowest target, $475, sits above it. At about 26x forward earnings, Synopsys costs more than the other two, but it’s also the one where the Street sees real room to run.

Synopsys is the one I’d follow

Target’s turnaround is real, and AbbVie’s quarter was excellent. But both stocks have already climbed to within a few percent of where Wall Street thinks they’re headed.

If I could only buy one of the three right now, it’d be Synopsys. It’s the only one of the three where the business has outrun the stock.

The risk is that the gap has been there all year: the average target sat at $556 a year ago, when the stock was at $393.93, and the stock has yet to close it. Synopsys also assumes no further changes to US export controls in its outlook, so trade policy could hit it. Its next report, in early December, is the next test, and the fund’s next 13F, due in mid-February, will show whether it kept adding.

So what is Target stock actually worth?

TIKR lets you forecast the future price of any stock in less than a minute. Just enter a few assumptions into TIKR’s valuation model and see what Target could be worth. Start from Wall Street consensus estimates, or adjust the inputs to reflect your own view of the business. It’s free to use.

Value Target for free

Disclaimer:

Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any of the stocks mentioned. Thank you for reading, and happy investing!

Join thousands of investors worldwide who use TIKR to supercharge their investment analysis.

Sign Up for FREENo credit card required